Startups
Lumos Pharma, a clinical stage biopharmaceutical company, is passionately focused on developing ther
Overview
Location
United States, Texas, Austin
Employees
11-50
Total raised
$48M
Founded date
1999
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Feb 5, 2014 | Series A round | $14M |
Mentions in press and media 22
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 3, 2023 | Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates | /EIN News/ -- -- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 -- -- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 – -- Confere... |
| Nov 3, 2021 | Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates - Form 8-K | Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates •Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sites •Six-month primary outc... |
| Aug 5, 2021 | Lumos Pharma : Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates | • Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and O... |
| Aug 3, 2021 | Lumos Pharma : Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer | AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, Da... |
| Aug 3, 2021 | Lumos Pharma : Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer (Form 8-K) | Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer AUSTIN, TX, August 3, 2021 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics f... |
| Aug 2, 2021 | Lumos Pharma : Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President | AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific... |
| Aug 2, 2021 | Lumos Pharma : Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President (Form 8-K) | Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President AUSTIN, TX, August 2, 2021 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for ra... |
| Jul 21, 2021 | Lumos Pharma : Announces Clinical Updates (Form 8-K) | Lumos Pharma Announces Clinical Updates •OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 months •OraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be ... |
| Jun 29, 2021 | Lumos Pharma : Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment (Form 8-K) | Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AU... |
Show more
Reviews 0
FAQ about Lumos Pharma
When was Lumos Pharma founded?
Lumos Pharma was founded in 1999.
How much funding has Lumos Pharma raised?
Lumos Pharma has raised $48M in total across 2 funding rounds.
What funding rounds has Lumos Pharma raised?
Parsers VC lists 2 funding rounds of Lumos Pharma, among them a Series A round of $14M on Feb 5, 2014.
What has the press written about Lumos Pharma?
Parsers VC has collected 22 articles mentioning Lumos Pharma, among them “Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates” (May 3, 2023) and “Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates - Form 8-K” (Nov 3, 2021).
Is Lumos Pharma still active?
Yes, Lumos Pharma is active; its latest activity on Parsers VC dates from Mar 7, 2024.